Reykjavik  (January 18, 2022) — Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (“Oaktree II”) (NYSE: OACB), a publicly traded special

Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market. High-concentration formulations, previously unavailable in Canada, reflect over 80% of use in the US Market.

Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the European Union (EU) follows the recommendation of the Committee for Medicinal Products

-       Alvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly growing category of highly efficacious medicines -       Transaction will

U.S. Federal Judge Grants Alvotech’s Motion to Dismiss AbbVie’s lawsuit alleging misappropriation of trade secrets. A U.S. federal judge has dismissed a lawsuit brought by AbbVie against Alvotech Hf alleging theft of trade secrets. Alvotech, is seeking to bring an affordable high-concentration

Reykjavik, Iceland (September 20, 2021) –  Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, today announced that the FDA is deferring action on the application for AVT02, the company’s proposed

Alvotech, today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira® (adalimumab).  The CHMP’s positive opinion will

Approximately 530 participants will be enrolled in a comparative, confirmatory efficacy and safety study for AVT04 in plaque psoriasis, across Central and Eastern European countries.  AVT04 Pharmacokinetic (PK) comparability study in approximately 294 healthy volunteers is being conducted

Funds provide additional resources and runway for advancing the company's biosimilar pipeline. Reykjavik, Iceland June 24, 2021  – Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m convertible bond issued on December

Alvotech’s Proposed Interchangeable Product for High-Concentration Humira® Could Save U.S. Consumers and Taxpayers Billions Annually In May of 2021, Alvotech USA Inc. Sued to End AbbVie’s Wrongful Monopoly on Humira and Bring an Affordable Arthritis Treatment to the U.S.